Apellis Pharmaceuticals, Inc. (APLS) News
Filter APLS News Items
APLS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APLS News Highlights
- APLS's 30 day story count now stands at 10.
- Over the past 23 days, the trend for APLS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- DEC, DRUG and EYE are the most mentioned tickers in articles about APLS.
Latest APLS News From Around the Web
Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted ConferenceWALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the even |
Wall Street Analysts Just Trimmed Price Targets for These 10 StocksIn this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. In the latest market developments on December 18, Asian stocks experienced a notable decline, […] |
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GAThe CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines. |
Apellis Crashes 17% As It Stares Down A Likely European RejectionApellis said Thursday it expects European regulators to reject its eye disease drug, Syfovre. APLS stock tumbled below its 200-day line. |
UPDATE 1-Apellis says EU regulator panel may not back its eye disease drugApellis Pharmaceuticals said on Thursday the European drug regulator's advisory panel may decline to back an authorization for its drug to treat a chronic eye disease, sending its shares down more than 14% in premarket trading. The company said it was informed on Wednesday that the panel may vote against the drug, a form of pegcetacoplan directly injected in the back of the eye, at the next meeting on Jan. 22-25. |
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European UnionConference call today at 8:30 a.m. ETWALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following the oral explanation meeting on |
Apellis eye drug likely to be rejected in Europe, company saysAccording to Apellis executives, reviewers in Europe are skeptical of the benefits of its geographic atrophy medicine, Syfovre, and appear poised to recommend against approval at a meeting next month. |
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual MeetingRapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal infection observed over three years in this analysisData shared during an oral presentation WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI® (pegcetacop |
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company approved the grant of equity awards to 4 new employees with a grant date of December 1, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq L |
Nike assumed at Buy, 'near-term challenges well understood': 4 big analyst picksHere is your Pro Recap of the biggest analyst picks you may have missed since yesterday: Buy assumptions at Nike and Block, and upgrades at Crown Castle and Apellis Pharmaceuticals. Goldman Sachs assumed coverage on Nike (NYSE:NKE) with a Buy rating and a price target of $139.00 (from $136 prior), as reported in real-time on InvestingPro. The analysts expect an upturn in Nike's earnings growth. |